Experimental justification of the use of “non-antiepileptic” drugs in complex pharmacotherapy of refractory epilepsy

Abstract

One of the possible ways if not to overcome the resistance of refractory epilepsy, then at least to conditionally stable control of seizures due to a decrease in disease activity, can be considered the use in addition to classical antiepileptic drugs (AEDs) medicines from other pharmacological groups – the socalled “non- antiepileptic” drugs. The presence of intrinsic anticonvulsant properties has been es- tablished in antiarrhythmic drugs (sodium, potassium and calcium channel blockers, β-adrenergic blockers), cardiac glycosides, arachidonic acid cascade inhibitors (non- steroidal anti-inflammatory drugs, dual inhibitors of COX-2/5-LOX enzymes, leuko- triene receptor blockers), antidiabetic drugs (metformin, incretins, inhibitors of sodi- um-dependent glucose cotransporter type 2), statins, xanthine oxidase inhibitors, etc. However, the ability of these drugs to influence the anticonvulsant potential of classi- cal AEDs has not been studied.